The 2009 H1N1 pandemic and recent human cases of H5N1, H7N9, and H6N1 in Asia highlight the need for a universal influenza vaccine that can provide cross-strain or even cross-subtype protection. Here, we show that recombinant monoglycosylated hemagglutinin (HA mg ) with an intact protein structure from either seasonal or pandemic H1N1 can be used as a vaccine for cross-strain protection against various H1N1 viruses in circulation from 1933 to 2009 in mice and ferrets. In the HA mg vaccine, highly conserved sequences that were originally covered by glycans in the fully glycosylated HA (HA fg ) are exposed and thus, are better engulfed by dendritic cells (DCs), stimulated better DC maturation, and induced more CD8+ memory T cells and IgG-secreting plasma cells. Single B-cell RT-PCR followed by sequence analysis revealed that the HA mg vaccine activated more diverse B-cell repertoires than the HA fg vaccine and produced antibodies with cross-strain binding ability. In summary, the HA mg vaccine elicits cross-strain immune responses that may mitigate the current need for yearly reformulation of strain-specific inactivated vaccines. This strategy may also map a new direction for universal vaccine design.
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glycoprotein engineering | broadly neutralizing antibody H A glycoprotein on the surface of influenza virus is a major target for infectivity-neutralizing antibodies. However, the antigenic drift and shift of this protein mean that influenza vaccines must be reformulated annually to include HA proteins of the viral strains predicted for the upcoming flu season (1) . This time-consuming annual reconfiguration process has led to efforts to develop new strategies and identify conserved epitopes recognized by broadly neutralizing antibodies as the basis for designing universal vaccines to elicit antibodies with a broad protection against various strains of influenza infection (2) (3) (4) (5) (6) . Previous studies have shown that the stem region of HA is more conserved and able to induce cross-reactive and broadly neutralizing antibodies (7) (8) (9) to prevent the critical fusion of viral and endosomal membranes in the influenza lifecycle (10) (11) (12) (13) (14) . Other broadly neutralizing antibodies have been found to bind regions near the receptor binding site of the globular domain, although these antibodies are fewer in number (15, 16) .
Posttranslational glycosylation of HA plays an important role in the lifecycle of the influenza virus and also contributes to the structural integrity of HA and the poor immune response of the infected hosts. Previously, we trimmed down the size of glycans on avian influenza H5N1 HA with enzymes and showed that H5N1 HA with a single N-linked GlcNAc at each glycosylation site [monoglycosylated HA (HA mg )] produces a superior vaccine with more enhanced antibody response and neutralization activity against the homologous influenza virus than the fully glycosylated HA (HA fg ) (17) . Here, to test whether the removal of glycans from HA contributes to better immune responses and possibly protects against heterologous strains of influenza viruses, we compared and evaluated the efficacy of HA glycoproteins with various lengths of glycans as potential vaccine candidates.
Results
HA fg , HA mg , and unglycosylated HA (HA ug ) proteins were prepared using secreted constructs of HA from the A/Brisbane/59/ 2007 (Bris/07) and A/California/07/2009 (Cal/09) H1N1 strains ( Fig. 1A and see Fig. S2A ). Because HA ug is obtained after treatment with the glycosidase PNGase F, each glycosylation site has an amino acid change from asparagine (Asn) to aspartic acid (Asp). The HA proteins are trimeric in solution ( Fig. S1 C-F) , and their compositions and secondary structures can be confirmed by MS and CD ( Fig. S1 G-J). HA fg and HA mg were found to have the same secondary structure, and HA ug showed a slight difference ( Fig. S1 G and I) . The glycan profile of each glycosylation site on HA was next determined by glycan peptide analysis (Table S1 ). In addition, glycan microarray analysis showed that the HA from either Cal/09 or Bris/07 binds to sialosides with an α2,6 linkage and that shortening the N-glycans on HA increases the binding avidity (Fig. 1B and Fig. S2B ). These HA proteins were used as vaccines in mice to analyze their ability to induce crossprotective immune responses.
Mice antisera were collected and tested for HA inhibition (HI) and microneutralization (MN) against the Cal/09 vaccine strain NIBRG-121 (Cal/09), A/WSN/1933 (WSN/33), and A/Puerto Rico/8/1934 (PR8/34) viruses (Fig. 1) . Compared with HA fg and HA ug , the antisera from HA mg -vaccinated mice were found to have higher HI titer (≧40) against all three viruses and exhibit higher neutralizing capacity to WSN/33 and Cal/09 viruses, whereas
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This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1323954111/-/DCSupplemental. no significant differences were observed among the three protein vaccines against PR8/34 virus. To test whether vaccination with HA mg offered cross-protection against these three H1N1 viruses, the immunized mice were challenged with lethal doses (100 LD 50 ) of Cal/09, WSN/33, and PR8/34 viruses, and the efficacy of vaccine protection was evaluated over 14 d based on survival rate (Fig. 1) . After virus challenge, mice vaccinated with PBS died before day 8 (Fig. 1) . A previous study using inactivated Bris/07 virus as a vaccine reported that it provided 30% protection against challenge with the 2009 pandemic A(H1N1) virus. In this study, Bris/07 HA fg showed a comparable level of protection (20%) against a lethal Cal/09 challenge. However, to our surprise, immunization with Bris/07 HA mg offered 70% protection against Cal/09 challenge ( (J) MN assay and (K) survival rate of virus challenge. GMT, geometric mean titer. *P < 0.05; **P < 0.01; ***P < 0.001. (Fig. S2) . The HA ug vaccines were found to be similar or in most cases, worse than HA mg in cross-strain protection. The reason behind this result is not clear and needs to be investigated, but it could be because HA ug contains partial glycans, which are not completely removed by enzyme (Table S1 ), has slight differences in the secondary structure ( Fig. S1 G and I) , and has the amino acid changes from Asn to Asp at each glycosylation site. We next investigated the underlying immune responses that may contribute to the cross-protectivity of HA mg vaccine. To this end, we first examined whether Bris/07 HA fg and HA mg initiated differential activation of dendritic cells (DCs), the immune sentinels that can detect, process, and present antigens to prime adaptive immune responses. We found that, compared with HA fg , HA mg was engulfed more readily by DCs ( Fig. 2A) and induced the increased expression of the activation marker (Fig. S3A ) and the elevated production of cytokines/chemokines (Fig. S3B) . Also, more splenic CD8+ granzyme B-secreting T cells were induced in Bris/07 HA mg -vaccinated mice challenged with Bris/07 or Cal/09 HA fg (Fig. 2E) , suggesting that HA mg vaccine induced stronger CD8+ cytotoxicity effects than HA fg . However, the enhanced activation of DCs by HA mg was not linked to better CD4+ T-cell responses, because total splenocytes or CD4+ T cells from Bris/07 HA fg or HA mg -vaccinated mice produced similar levels of IL-2 (Fig. 2B) , CD4+INFγ+ Th1 cells (Fig. 2C) , and CD4+IL-4+ Th2 cells (Fig. 2D) when challenged with Bris/07 HA fg , Cal/09 HA fg , or DCs loaded with these proteins. Although HA mg did not induce better CD4+ T-helper responses, more HA-specific antibodysecreting cells were produced in Bris/07 HA mg -vaccinated mice, and they showed cross-recognition (Fig. 2F) , consistent with our findings that HA mg induced higher levels of cross-protective antibodies. Given that CD4+ T-helper responses were not promoted but HA-specific antibody-secreting cells were increased in HA mg -vaccinated mice, we suspect that B cells may functionally and specifically recognize the intact structure of HA mg , because all HA glycoproteins used in this study were in their trimeric forms. Vaccine efficacy had the potential for modulation by the structural integrity of HA proteins, because antisera from the mice vaccinated with the heat-denatured form of Cal/09 HA mg or the monomeric form of Cal/09 HA mg (Fig. S1) showed highly reduced HI titers (Fig. 2G) ; additionally, the vaccines showed decreased protection levels compared with the trimeric forms (Fig. 2H) . These results suggest that intact trimeric HA mg may reveal extra epitopes that are recognized by B cells and result in the production of different antibodies or simply, that the trimeric protein is a better activator of B cells than the monomer to induce better antibodies. Next, the sera from immunized mice were incubated with the HA from a heterologous strain coated on Sepharose beads, and the flow-through sera were then subjected to MN experiments against various H1N1 viruses. A reduction in the MN activity of the flow-through sera would indicate that the antibodies bound to the HA of the heterologous strain contribute to the observed cross-strain neutralization ability. We observed stronger neutralizing activity from the sera of HA mg vaccination, indicating that the compositions of induced antibodies from HA mg and HA fg are different and that the antibodies from HA mg exhibit stronger cross-strain neutralizing activity. If this implication were not the case, we would expect to observe the same percentage of neutralization inhibition (Fig. S4 A-F) . When HA ug was coated on the beads, the stronger neutralizing activity of HA mg over HA fg immunization was no longer observed (Fig. S4 G-I) . Because HA ug carries a negative charge (Asp residue) at each glycosylation site that may prevent the binding of neutralizing antibodies, this observation strengthens the idea that the extra cross-strain neutralizing antibodies from HA mg vaccination recognize the conserved epitopes near the glycosylation sites.
To better understand the B-cell repertoires after immunization with HA mg or HA fg , about 200 single splenic B cells capable of binding to Bris/07 HA fg from the spleens of Bris/07 HA fg -or HA mg -vaccinated mice were sorted. By analyzing the amino acid sequences of the RT-PCR products of the variable regions of Ig heavy-chain (IgH) and Ig light-chain (IgL) genes from about 70 individual single B cells that contained detectable PCR signals (Fig. 3A) , we were able to profile the HA-specific B-cell repertoire elicited by HA mg vaccination and found that HA mg response was more complex than that of HA fg . Some HA-specific B cells with particular compositions of IgH and κ-IgL or λ-IgL loci were clonally amplified in HA mg -vaccinated mice (Fig. 3 B  and C) . Particularly, compared with HA fg -vaccinated mice, at least five HA-specific B-cell clones were selectively amplified by the HA mg vaccine (Fig. 3 B and C) . These amplified clones had undergone somatic hypermutation in the germinal center, because each single B cell within the clonally amplified populations carried various frequencies of mutation in the variable region of IgH and IgL genes ( Fig. S5 and Table S2 ).
We next wondered whether these differentially expanded B-cell clones recognize the epitopes exposed after the removal of the glycans on HA. To this end, variable regions of heavy-and light-chain genes from the amplified HA-specific B-cell clones were measured in nasal washes collected on indicated days and after serial titration by using plague forming unit (PFU) assay. (F) The inoculated ferrets were euthanized on day 4, and the lung viral titers were also measured with PFU assay. *P < 0.05; **P < 0.01; ***P < 0.001.
were further subcloned into an expression vector to produce recombinant antibodies for analysis of their binding to the HA of diverse influenza virus strains, including Bris/07, Cal/09, WSN/33, PR8/34, H3, H5, and Flu B viruses (Fig. 3D) . The Ig vector control antibody, which cannot recognize HA, served as a negative control, and the positive control monoclonal antibody F10 with broad neutralizing activity (12) can only bind to the HA from Bris/07 and Cal/09 (Fig. 3D) under the same dilution condition used for the other tested antibodies. Two recombinant monoclonal antibodies, clones 557 and 621, generated in this study were further examined. We found that clone 557 binds to the HA from Cal/09 better than to the HA from Bris/07, WSN/ 33, and H3 but not to the HA from PR8/34 and Flu B; we also found that clone 621 binds to all tested HAs, except the HA from the H5 virus, suggesting that the HA-specific B-cell clones identified here may recognize a broad spectrum of influenza viruses. Moreover, the antibodies produced by clones 557 and 621 bound Bris/07 and Cal/09 HA mg more strongly than HA fg or HA ug (Fig. 3E) , suggesting that additional epitopes near or at the glycan sites of HA may be recognized by the HA mg -induced antibodies. Sequence similarity search of the glycosylation site sequences (12 aa N-and C-terminal to Asn residue, a total of 25 aa for each glycosylation site) from either Bris/07 or Cal/09 HA was performed against human proteome by using BLAST (http:// blast.ncbi.nlm.nih.gov), and no significant hits were found, implying that adverse cross-reactivity with human proteins may not be expected when vaccinated with HA mg . Cross-strain neutralization and protection induced by HA mg vaccination were also tested in ferrets. Human and avian influenza viruses can replicate efficiently in the respiratory tract of ferrets without prior adaptation (18). The specificity of the resulting immune responses indicated that the antisera from the Bris/07 HA mg -immunized ferrets were able to neutralize Cal/09, WSN/33, and PR8/34 viruses with a significantly higher titer compared with the antisera from HA fg vaccination (Fig. 4 A-C) . Similar cross-reactivity was also observed in the HI assay (Fig. 4D) . Significantly lower virus titers in the washes of nasal turbinates at days 1 and 3 after infection were observed from the HA mg -vaccinated ferrets (Fig. 4E) , and virus growth and replication were consistently considerably lower in the lung tissues from the HA mg -vaccinated ferrets (Fig. 4F) .
Discussion
Antigenic drift, mostly caused by the accumulation of mutations in HA, is the major cause of the frequent failure of influenza vaccines from previous seasons to provide good protection against currently circulating influenza strains (19) . Changes in epitopes, including the occasional addition or removal of glycosylation sites, escape host immune recognition (20) (21) (22) . The complexity and variation of glycosylation on HA are, thus, important factors to be considered in influenza vaccine design. In addition, the 20% difference in the HA sequence in Bris/07 and Cal/09 is mostly on the surface where glycosylation takes place, whereas the sequences in the interior regions are relatively unchanged (23) . A consensus HA-based DNA vaccine has been shown to protect against diverse avian influenza viruses (24) . This study opens the door to the possibility of design of a consensus HA glycoprotein vaccine in monoglycosylated form that can protect against a broad range of seasonal and pandemic influenza viruses.
Materials and Methods
DNA sequences of recombinant HAs are from H1N1 strains of Cal/09 and Bris/07 and synthesized with codons optimized for human cell expression. HAs with different glycosylations were produced by transient transfection of expression vectors in 293 EBNA or 293S cells (ATCC), purified by affinity chromatography, and treated with Endo H or PNGase F (New England Biolabs). All animal experiments were carried out in accordance with the Institutional Animal Care and Use Committee of Academia Sinica. Mice and ferrets were immunized intramuscularly with HA (20 and 50 μg, respectively) and 50 μg Alum (Sigma) at weeks 0 and 2, blood was collected at week 4, and virus challenges were performed at week 5. Statistical analyses were by the program Prism (GraphPad Software). More details are in SI Materials and Methods.
